Through the generation of adenosine and suppression of ATP-mediated inflammatory signaling, CD39 promotes the expansion of immunosuppressive cell subsets, facilitates VEGF-dependent angiogenesis, and supports metabolic programs—such as oxidative phosphorylation and lipid utilization—that enable tumor survival and progression. This evidence concerns the gene ENTPD1 and neoplasm.